A review of emerging therapeutic potential of psychedelic drugs in the treatment of psychiatric illnesses

Chi and Gold frame psychedelics as a class of compounds with a long anthropological and early clinical history, noting renewed scientific interest after decades of prohibition. Modern interest follows the initial discovery and distribution of LSD and psilocybin in the mid-20th century, a period of enthusiastic but methodologically inconsistent research that ended after widespread recreational use prompted political backlash and the US Controlled Substances Act of 1970. The authors distinguish classic psychedelics (LSD, psilocybin, DMT) that act primarily as 5-HT2A agonists from entactogens such as MDMA, which primarily modulate monoamine transporters, and they note overlapping but distinct neurobiological hypotheses for therapeutic action, including changes in neuroplasticity, altered amygdala responsivity, and engagement of signalling pathways such as mTOR.

This paper is an expert narrative review rather than a systematic review or meta-analysis. The study team reviewed major peer-reviewed human studies and NIH-registered clinical trials concerning selected psychedelic drugs: psilocybin, LSD, DMT (ayahuasca-related literature is mentioned), and MDMA. The authors synthesised safety data, controlled trials, open-label studies, small pilot investigations, and historical randomized trials, citing pooled analyses where available. The extracted text does not report a formal search strategy, inclusion/exclusion criteria, database list, dates searched, or a formal risk-of-bias assessment; consequently, this review appears to be selective and interpretive rather than adhering to systematic-review methodology.

Psilocybin: Safety data pooled by Studerus et al. from eight double-blind, placebo-controlled studies (1999–2008) covered 277 psilocybin sessions in 110 healthy subjects and indicated generally good short- and long-term tolerability, with common transient adverse effects such as fatigue and headaches and rare prolonged emotional disturbance that resolved with psychotherapy. A Hopkins study of 18 volunteers examined headache specifically and judged psilocybin-associated headaches to be neither severe nor disabling. In clinical populations, early pilot and randomized studies targeted end-of-life anxiety and depression and treatment-resistant depression. A 2010 Harbor‑UCLA double-blind pilot in 12 advanced-cancer patients found no statistically significant change in mood or anxiety but demonstrated feasibility and no serious adverse events. A 2016 Johns Hopkins randomized, double-blind, crossover trial in 51 cancer patients compared very low versus high psilocybin doses and reported strong benefit: 92% of participants showed either clinical remission or a ≥50% reduction in depressive symptoms on GRID-HAMD-17, and >75% improved on HAM-A, with benefits persisting at 5 weeks and no medically serious adverse events. A contemporaneous NYU blinded crossover study using niacin as active control (29 patients) found >80% antidepressant response with psilocybin versus 14% with niacin, and 58% versus 14% for anxiety; many subjects maintained improvement at 6.5 months. Limitations noted across trials included selection bias, incomplete blinding (staff correctly guessed assignment in 97% of cases in one study), and possible expectancy effects. For treatment-resistant depression, an open-label London study of 12 patients reported 67% clinical remission after two psilocybin sessions, with 58% maintaining response at three months and only transient, non-serious adverse events. In obsessive-compulsive disorder, a small University of Arizona proof-of-concept study in nine subjects who had prior psychedelic exposure reported acute YBOCS reductions of 23–100% at 24 hours, but effects largely reverted within a week. A 15-person open pilot for tobacco cessation that combined three psilocybin sessions with structured behavioural therapy found 80% seven-day point-prevalence abstinence at six months and 67% abstinence at 12 months, substantially higher than typical cessation aids; the cohort was self-selected and motivated, limiting generalisability. LSD: Contemporary placebo-controlled studies in about 100 healthy volunteers (doses 40–200 μg) found that LSD produces acute psychotomimetic effects (delusional thinking, perceptual distortion) that are transient, alongside reported increases in positive mood and openness. Physiological effects were transient increases in blood pressure, heart rate and temperature; common post-experiment symptoms included headache, exhaustion and anxiety that resolved. A double-blind, active placebo-controlled trial in 12 patients with life‑threatening illness (two 200 μg sessions versus 20 μg active placebo) showed a non-significant primary outcome but a trend toward reduced anxiety and no enduring LSD-attributed harms. A meta-analysis of six randomized trials from 1966–1970 (536 adults with alcoholism) found that a single LSD dose (200–800 μg) was associated with reduced problematic drinking at 2–6 months, with a number needed to treat (NNT) of 6 for improvement; studies varied in preparatory and psychotherapeutic support. MDMA: Historical and prospective data on MDMA have been more mixed, with concerns raised from animal studies about serotonergic neurotoxicity and from observational studies of recreational users about impaired cortical auditory responses. Prospective human laboratory data pooled from nine placebo-controlled crossover studies in Basel (166 healthy subjects) confirmed dose‑dependent cardiovascular and thermoregulatory effects, with maximal recorded systolic/diastolic blood pressures of 196/130 mmHg and maximal temperature 39.1 °C in the pooled sample. Acute adverse effects recorded more frequently in MDMA recipients versus placebo included lack of appetite (59% v 1%), dry mouth (55% v 1%), difficulty concentrating (46% v 4%), and bruxism (40% v 2%); no hypertensive emergencies or hyperpyrexia >40 °C were reported in these trials, and no serious long-term organ toxicity was observed in the short follow-up. MDMA for PTSD: Early MDMA-assisted psychotherapy trials have shown promising effects. A 2010 MAPS randomized, double‑blind, placebo‑controlled pilot (20 participants) used two 8‑hour MDMA (125 mg) or placebo sessions plus manualised psychotherapy; at two months after the second session the clinical response (>30% CAPS reduction) was 83% (10/12) in the MDMA group versus 25% (2/8) in placebo, and 10 MDMA recipients no longer met DSM‑IV PTSD criteria compared with two in placebo. Long-term follow-up (mean 45 months) in 16/20 participants indicated sustained improvement; no persistent medical or psychiatric adverse effects were observed. A New Zealand replication did not find a statistically significant benefit of MDMA-assisted psychotherapy over psychotherapy alone, and the MAPS programme subsequently ran six Phase II trials across five sites enrolling 105 patients in total (31 control, 74 active) with active doses from 75–125 mg. The text reports heterogeneity in outcomes across studies and calls for larger trials; the MAPS programme advanced to later‑phase testing after these encouraging Phase II data. Across studies, authors consistently report small samples, incomplete blinding, selection bias (often predominantly white, sometimes with prior psychedelic exposure), and limited long-term safety data as important constraints on interpreting efficacy and safety.

Chi and colleagues interpret the assembled literature as indicating that selected psychedelic medicines show therapeutic promise for psychiatric disorders that are refractory to conventional treatments, including end-of-life anxiety, treatment-resistant depression, PTSD and substance use disorders. They emphasise that contemporary studies, unlike many early trials, use careful protocols with psychotherapeutic support and institutional oversight, and that reported adverse effects have generally been transient and non-life-threatening when substances are administered in controlled settings. The authors highlight mechanistic leads—changes in neuroplasticity, amygdala responsivity, and mTOR-related signalling—that may help explain therapeutic effects, but they note that biological mechanisms remain incompletely understood. Key limitations acknowledged by the authors include small sample sizes, selection biases (for example, prior psychedelic exposure and predominantly Caucasian samples), and difficulty maintaining blinding because of the characteristic subjective effects of these drugs, which may introduce expectancy effects. They also note that much of the MDMA safety literature is heterogeneous and that long-term safety and the possibility of dose-dependent harms remain incompletely characterised. Historical, regulatory and societal factors—most notably the Schedule I classification—have constrained large-scale government-funded research and complicated public discourse. In terms of implications, the authors argue for continued controlled clinical research and careful translation into practice, stressing the need for strategies to mitigate diversion, abuse and misinformation. They caution against premature or uncontrolled dissemination, pointing to emerging public trends such as unsupported microdosing practices. At the same time, the review suggests that, if ongoing trials continue to demonstrate favourable benefit–risk profiles, psychedelics could become important adjuncts or alternatives in select, treatment‑refractory psychiatric populations. The authors call for larger, methodologically rigorous trials, longer follow-up for safety outcomes, and thoughtful policy planning to balance access with safeguards.